PDD Holdings Inc. (LON:0A2S)

Theseus Pharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	70,126	57,768	59,794	34,326	6,427	22,421
Short-Term Investments	294,375	273,792	157,415	115,106	86,203	61,549
Trading Asset Securities	-	-	-	6.92	313.32	3,002
Cash & Short-Term Investments	364,501	331,560	217,210	149,439	92,943	86,972
Cash Growth	50.54%	52.64%	45.35%	60.78%	6.87%	111.83%
Accounts Receivable	12,887	7,107	10,632	3,352	3,477	3,907
Other Receivables	-	3,636	367	3,303	1,784	1,046
Receivables	12,887	11,454	11,709	7,353	5,959	5,651
Inventory	-	-	-	-	-	1,718
Prepaid Expenses	5,255	1,357	1,326	966.44	-	-
Restricted Cash	65,132	68,426	61,985	57,974	59,617	52,422
Other Current Assets	-	2,851	2,520	885.95	2,390	2,760
Total Current Assets	447,774	415,648	294,750	216,618	160,909	149,524
Property, Plant & Equipment	6,432	5,944	5,084	2,461	3,142	832.68
Long-Term Investments	-	82,974	47,524	16,665	16,268	6,839
Other Intangible Assets	18.22	19.17	21.15	134	701.22	1,277
Long-Term Deferred Tax Assets	62.76	16	270.74	1,045	31.5	-
Other Long-Term Assets	76,226	433.23	426.91	196.74	158.01	436.15
Total Assets	530,513	505,034	348,078	237,120	181,210	158,909
Accounts Payable	93,625	120,738	93,141	68,972	66,424	58,357
Accrued Expenses	76,207	37,903	33,614	15,186	11,336	9,241
Short-Term Debt	-	-	-	-	-	1,866
Current Portion of Long-Term Debt	5,302	5,310	648.57	13,886	-	-
Current Portion of Leases	2,325	2,106	1,642	602.04	427.16	253.04
Current Unearned Revenue	2,945	2,947	2,145	1,390	1,167	2,423
Other Current Liabilities	16,620	19,419	21,711	16,854	14,375	11,741
Total Current Liabilities	197,025	188,423	152,901	116,889	93,730	83,882
Long-Term Debt	-	-	5,232	1,576	11,789	14,433
Long-Term Leases	3,626	3,192	2,644	870.78	544.26	414.94
Long-Term Deferred Tax Liabilities	161.51	106.77	59.83	13.03	31.29	-
Other Long-Term Liabilities	-	-	-	-	1	2.92
Total Liabilities	200,812	191,721	160,837	119,349	106,095	98,733
Common Stock	0.18	0.18	0.18	0.17	0.16	0.16
Additional Paid-In Capital	120,004	117,829	107,293	99,250	95,341	86,699
Retained Earnings	202,401	187,659	75,225	15,198	-17,707	-25,475
Comprehensive Income & Other	7,297	7,825	4,724	3,322	-2,520	-1,048
Total Common Equity	329,701	313,313	187,242	117,771	75,115	60,176
Shareholders' Equity	329,701	313,313	187,242	117,771	75,115	60,176
Total Liabilities & Equity	530,513	505,034	348,078	237,120	181,210	158,909
Total Debt	11,253	10,607	10,166	16,934	12,760	16,967
Net Cash (Debt)	353,248	320,953	207,044	132,504	80,183	70,005
Net Cash Growth	51.84%	55.02%	56.25%	65.25%	14.54%	103.46%
Net Cash Per Share	238.56	216.98	141.82	92.00	56.13	58.72
Filing Date Shares Outstanding	1,392	1,420	1,389	1,329	1,264	1,253
Total Common Shares Outstanding	1,392	1,392	1,376	1,320	1,264	1,239
Working Capital	250,749	227,225	141,850	99,728	67,179	65,642
Book Value Per Share	236.86	225.06	136.09	89.25	59.41	48.58
Tangible Book Value	329,683	313,294	187,220	117,637	74,413	58,899
Tangible Book Value Per Share	236.85	225.04	136.07	89.15	58.85	47.55
Machinery	-	4,676	4,150	3,592	3,135	229.39
Leasehold Improvements	-	128.74	69.69	30.25	28.77	23.78

Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.